Corinne M. Linardic, MD, PhD

AddThis

Print

email this


Associate Professor of Pediatrics
Department / Division:
Pediatrics / Pediatrics-Hematology/Oncology
Address:
DUMC 102382
Durham, NC 27710
Appointment Telephone:
919-684-3401
Office Telephone:
919-684-3401
Fax:
919-681-7950
Training:
  • MD, Duke University School of Medicine, 1995
Residency:
  • Pediatrics, Children's Hospital of Philadelphia (Pennsylvania), 1995-1998
Fellowship:
  • Pediatric Hematology-Oncology, Children's Hospital of Philadelphia (Pennsylvania), 1998-1999
  • Pediatric Hematology-Oncology, Duke University Medical Center, 1999-2001
Other Training:
  • PhD, Cell Biology, Duke University, 1993
Clinical Interests:
Pediatric hematology-oncology with emphasis on caring for children, adolescents, young adults with sarcomas
Research Interests:
Pediatric Sarcomas: Sarcomas are among the most difficult-to-treat cancers in pediatric oncology, with metastatic forms having the highest mortality. We have established genetically defined human cell-based models for the pediatric skeletal muscle cancer known as rhabdomyosarcoma. Current therapies are based on xenograft models in immunocompromised mice, using established patient-derived patient cell lines, but because of the genetic variability of these cell lines, a true understanding of the causative role of certain genetic changes (e.g. chromosomal translocations) in rhabdomyosarcoma formation is not understood. Specific goals of this research program include the identification of signaling pathways corrupted in rhabdomyosarcoma, with focus on the PAX3-FOXO1 mutation and its downstream effectors, and identification of new therapeutic targets for treatment of this childhood cancer.
Representative Publications:
  • Belyea, B; Kephart, JG; Blum, J; Kirsch, DG; Linardic, CM. Embryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targeting. Sarcoma. 2012;2012:406239.  Abstract
  • Crose, LE; Etheridge, KT; Chen, C; Belyea, B; Talbot, LJ; Bentley, RC; Linardic, CM. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Clinical Cancer Research. 2012;18:3780-3790.  Abstract
  • Ignatius, MS; Chen, E; Elpek, NM; Fuller, AZ; Tenente, IM; Clagg, R; Liu, S; Blackburn, JS; Linardic, CM; Rosenberg, AE; Nielsen, PG; Mempel, TR; Langenau, DM. In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma. Cancer Cell. 2012;21:680-693.  Abstract
  • Belyea, BC; Naini, S; Bentley, RC; Linardic, CM. Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis. Clinical Cancer Research. 2011;17:7324-7336.  Abstract
  • Crose, LE; Linardic, CM. Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma. Sarcoma. 2011;2011:756982.  Abstract
  • Linardic, CM. PAX3-FOXO1 fusion gene in rhabdomyosarcoma. Cancer Letters. 2008;270:10-18.  Abstract
  • Linardic, CM; Counter, CM. Genetic modeling of Ras-induced human rhabdomyosarcoma. Methods in Enzymology. 2008;438:419-427.  Abstract
  • Naini, S; Etheridge, KT; Adam, SJ; Qualman, SJ; Bentley, RC; Counter, CM; Linardic, CM. Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. Cancer Research. 2008;68:9583-9588.  Abstract
  • Linardic, CM; Naini, S; Herndon, JE; Kesserwan, C; Qualman, SJ; Counter, CM. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Cancer Research. 2007;67:6691-6699.  Abstract
  • Kendall, SD; Linardic, CM; Adam, SJ; Counter, CM. A network of genetic events sufficient to convert normal human cells to a tumorigenic state. Cancer Research. 2005;65:9824-9828.  Abstract
  • Linardic, CM; Downie, DL; Qualman, S; Bentley, RC; Counter, CM. Genetic modeling of human rhabdomyosarcoma. Cancer Research. 2005;65:4490-4495.  Abstract